Keywords: 4 years; interleukin 17; ixekizumab; long-term; open-label; psoriasis; BCC; basal cell carcinoma; DLQI; Dermatology Life Quality Index; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IL; interleukin; LOCF; last observation c
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: etanercept; long-term safety; open-label; pediatric population; plaque psoriasis; AE; adverse event; CDC; Centers for Disease Control and Prevention; FDA; Food and Drug Administration; HRQOL; health-related quality of life; JIA; juvenile idiopathic arthri
Keywords: Dermatology Life Quality Index; health-related quality of life; patient-reported outcomes; plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis Symptom Inventory; static Physician Global Assessment; DLQI; Dermatology Life Quality Index; HRQoL; h
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
Keywords: apremilast; nail psoriasis; phosphodiesterase 4 inhibitor; psoriasis; scalp psoriasis; systemic therapy; BID; twice daily; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; NAPSI; Nail Psoriasis Severity Index; NAPSI-50;
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
Keywords: IL-23A; mAb; psoriasis; pharmacokinetics; biomarkers; single dose; randomized; AE; Adverse event; AUEC; Area under the effect curve; DC-LAMP; Dendritic cell lysosome-associated membrane glycoprotein; Emax; Maximum effect; FC; Fold change; MACE; Major adve
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
Keywords: interleukin 17; ixekizumab; long-term; monoclonal antibodies; open label; psoriasis; 1 year; AE; adverse event; NRI; nonresponder imputation; OLE; open-label extension; PASI; Psoriasis Area and Severity Index; PASI75; 75% improvement from baseline on the
Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
Keywords: BSA; body surface area; HAHA; human anti-human antibody; ITT; intent-to-treat; IVRS; interactive voice response system; LFA-1; leukocyte function-associated antigen-1; PASI; Psoriasis Area and Severity Index; PASI-50; at least 50% reduction in PASI; PAS